Xilio Therapeutics (NASDAQ:XLO) Posts Earnings Results, Beats Estimates By $0.26 EPS

Xilio Therapeutics (NASDAQ:XLO) released its earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.26, FiscalAI reports. Xilio Therapeutics had a negative return on equity of 151.42% and a negative net margin of 58.52%.The company had revenue of $18.69 million during the quarter, compared to analysts’ expectations of $12.72 million.

Xilio Therapeutics Trading Up 0.2%

NASDAQ:XLO traded up $0.01 during trading hours on Thursday, reaching $9.06. 4,825 shares of the company traded hands, compared to its average volume of 40,493. The business’s 50-day moving average price is $8.86 and its two-hundred day moving average price is $8.36. The stock has a market capitalization of $59.65 million, a P/E ratio of -2.55 and a beta of -0.14. Xilio Therapeutics has a 1 year low of $6.47 and a 1 year high of $12.74.

Analysts Set New Price Targets

A number of equities analysts have issued reports on XLO shares. Wall Street Zen downgraded Xilio Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings downgraded shares of Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Xilio Therapeutics

Institutional investors have recently modified their holdings of the stock. Bain Capital Life Sciences Investors LLC boosted its stake in Xilio Therapeutics by 61.4% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,372,686 shares of the company’s stock worth $4,720,000 after purchasing an additional 2,805,869 shares in the last quarter. Ghisallo Capital Management LLC bought a new stake in Xilio Therapeutics during the 4th quarter valued at about $713,000. Velan Capital Investment Management LP purchased a new position in Xilio Therapeutics in the fourth quarter worth about $109,000. Renaissance Technologies LLC raised its holdings in Xilio Therapeutics by 68.3% in the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after buying an additional 139,716 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its stake in shares of Xilio Therapeutics by 39.6% in the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after buying an additional 93,338 shares in the last quarter. 54.29% of the stock is owned by hedge funds and other institutional investors.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.